Abstract
Introduction: Epilepsy is a major global health burden, affecting more than 70 million people worldwide. Approximately 20-30% of patients do not achieve adequate seizure control with currently available antiseizure medications. This study investigates novel triazin-5-one derivatives as potential antiseizure agents targeting the γ-aminobutyric acid (GABA) system. The compounds were designed to interact with GABAA receptors and inhibit GABA aminotransferase (GABA-AT), using lamotrigine as a reference antiseizure drug. This dual-target strategy may support the development of more effective therapies for drug-resistant epilepsy. Materials and Methods: Eighteen 6-(4-methoxybenzyl)-3-R-4H-[1,2,4]triazin-5-one derivatives (3a–r) were synthesized and characterized by 1H and 13C NMR spectroscopy, LC-MS, and elemental analysis. Molecular docking was performed against the GABAA receptor (PDB ID: 1OHV) and GABA-AT enzyme (PDB ID: 1SF2) to estimate binding affinity. GABA-AT inhibition was evaluated in vitro, and anticonvulsant activity was assessed in mouse models at doses equimolar to 10 mg/kg lamotrigine. Results: Compounds 3o, 3f, 3r, 3g, and 3h showed the highest predicted binding affinities for the GABAA receptor, with binding-energy magnitudes exceeding 10 kcal/mol. Compound 3h (3-(2,3-dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) exhibited the lowest IC50 value for GABA-AT inhibition (30.50 ± 0.61 μM), comparable to that of lamotrigine (32.7 ± 0.7 μM). In the animal model, compounds 3f and 3h completely suppressed clonic and recurrent clonic-tonic seizures. Docking analysis indicated that 3h forms hydrogen bonds with Arg430 and Ile426 through the triazine oxygen atom and interacts with His44 through a triazine nitrogen atom. Discussion: The anticonvulsant effects of these 1,2,4-triazine derivatives appear to depend on the substituents at positions 3 and 6 of the heterocyclic ring. Their potential dual mechanism, involving both receptor modulation and enzyme inhibition, may contribute to their neurotropic activity. Compound 3r contains a defined pharmacophore incorporating tryptamine and triazine fragments, whereas the spatial requirements underlying the activity of compound 3h remain unclear and require further structural investigation. Conclusion: The study identifies novel triazin-5-ones, specifically compounds 3h and 3f, as promising candidates for the development of new antiseizure therapies. These derivatives demonstrate potency and efficacy comparable to lamotrigine and may offer a multi-target mechanism within the GABAergic system.